Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Danaher Corporation reported second quarter 2026 results that reflected a combination of better-than-expected revenue, earnings, and cash flow, against a backdrop of mixed end-market conditions.</li><li>Total sales for the quarter reached $6.3 billion with core revenue growth of 3% year-over-year, accelerating to 4.5% when excluding respiratory testing revenue.</li><li>The company acknowledged shipment timing challenges in the Biotechnology segment, particularly within bioprocessing, which caused a delay in revenues but did not alter underlying demand trends as evidenced by robust mid-teens order growth in equipment and consumables.</li></ul>

Danaher Corporation reported second quarter 2026 results that reflected a combination of better-than-expected revenue, earnings, and cash flow, against a backdrop of mixed end-market conditions.Total sales for the quarter reached $6.3 billion with core revenue growth of 3% year-over-year, accelerating to 4.5% when excluding respiratory testing revenue.The company acknowledged shipment timing challenges in the Biotechnology segment, particularly within bioprocessing, which caused a delay in revenues but did not alter underlying demand trends as evidenced by robust mid-teens order growth in equipment and consumables.

Danaher Raises Guidance As Mid-Teens Bioprocessing Orders Signal A Rebound!

<ul><li>Danaher Corporation reported a first quarter 2026 with mixed yet generally stable financial and operational results amid a dynamic global environment.</li><li>The company generated $6.0 billion in sales, reflecting a modest 0.5% year-over-year core revenue increase.</li><li>This growth was tempered by a significant 2.5% headwind mainly from a lighter-than-typical respiratory season impacting Cepheid.</li></ul>

Danaher Corporation reported a first quarter 2026 with mixed yet generally stable financial and operational results amid a dynamic global environment.The company generated $6.0 billion in sales, reflecting a modest 0.5% year-over-year core revenue increase.This growth was tempered by a significant 2.5% headwind mainly from a lighter-than-typical respiratory season impacting Cepheid.

Danaher Corporation: China Headwinds Persist—But Is the Core Business Strong Enough to Offset?

<ul><li>Recent reports indicate that Danaher is nearing a roughly $10 billion acquisition of Masimo, a U.S.-based medical technology company best known for its pulse oximetry platforms and noninvasive patient monitoring solutions.</li><li>According to media coverage, the transaction could represent a significant premium to Masimo’s recent ~$7 billion market capitalization and would mark Danaher’s largest deal since its $21.4 billion acquisition of Cytiva in 2020.</li><li>The timing is notable.</li></ul>

Recent reports indicate that Danaher is nearing a roughly $10 billion acquisition of Masimo, a U.S.-based medical technology company best known for its pulse oximetry platforms and noninvasive patient monitoring solutions.According to media coverage, the transaction could represent a significant premium to Masimo’s recent ~$7 billion market capitalization and would mark Danaher’s largest deal since its $21.4 billion acquisition of Cytiva in 2020.The timing is notable.

Danaher’s Big Bet On Masimo: Hidden Synergies Or Integration Risk?

<ul><li>Danaher Corporation's fourth-quarter performance in 2025 exhibited a strong finish to the year, marked by better-than-expected performance across its expansive portfolio.</li><li>A key highlight was the continued strength in the bioprocessing business, as well as improving momentum in Diagnostics and Life Sciences.</li><li>This was achieved despite a dynamic geopolitical and policy environment.</li></ul>

Danaher Corporation's fourth-quarter performance in 2025 exhibited a strong finish to the year, marked by better-than-expected performance across its expansive portfolio.A key highlight was the continued strength in the bioprocessing business, as well as improving momentum in Diagnostics and Life Sciences.This was achieved despite a dynamic geopolitical and policy environment.

Danaher Corporation’s Diagnostics Reset: Why Policy Headwinds Are Turning Into Tailwinds!

<ul><li>Danaher Corp. could be nearing the end of its post-Covid slump as 2026 begins to take shape.</li><li>After multiple years of sluggish demand following the pandemic, the stock has lagged the broader market significantly, gaining just 11% over five years versus the S&P 500's 82% surge.</li><li>However, a convergence of macro and industry-specific tailwinds could mark a turning point for the company.</li></ul>

Danaher Corp. could be nearing the end of its post-Covid slump as 2026 begins to take shape.After multiple years of sluggish demand following the pandemic, the stock has lagged the broader market significantly, gaining just 11% over five years versus the S&P 500's 82% surge.However, a convergence of macro and industry-specific tailwinds could mark a turning point for the company.

Danaher’s Biopharma Boom: Why 2026 Could Be A Game-Changer!

United States

Danaher Corporation designs, manufactures, and markets professional, medical, industrial and commercial products, and services in the sectors of test and measurement, environmental, life sciences, dental, and industrial technologies.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Danaher (DHR UN)

Danaher Raises Guidance As Mid-Teens Bioprocessing Orders Signal A Rebound!

Danaher Corporation reported second quarter 2026 results that reflected a combination of better-than-expected revenue, earnings, and cash flow,...

Baptista Research

Danaher Corporation: China Headwinds Persist—But Is the Core Business Strong Enough to Offset?

Danaher Corporation reported a first quarter 2026 with mixed yet generally stable financial and operational results amid a dynamic global...

Baptista Research

Danaher’s Big Bet On Masimo: Hidden Synergies Or Integration Risk?

Recent reports indicate that Danaher is nearing a roughly $10 billion acquisition of Masimo, a U.S.-based medical technology company best known...

Baptista Research

Danaher Corporation’s Diagnostics Reset: Why Policy Headwinds Are Turning Into Tailwinds!

Danaher Corporation's fourth-quarter performance in 2025 exhibited a strong finish to the year, marked by better-than-expected performance across...

Baptista Research

Danaher’s Biopharma Boom: Why 2026 Could Be A Game-Changer!

Danaher Corp. could be nearing the end of its post-Covid slump as 2026 begins to take shape. After multiple years of sluggish demand following the...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)